Reinach, July 1, 2020 – Evolva (SIX:EVE), the Swiss biotech company, announced today that a 15-day public review period for nootkatone started in the US. This is a further step in the registration process.
The public review period comes after the acceptance of all the studies submitted to the US Environmental Protection Agency (EPA), and allows the general public to share comments on nootkatone with the government agency.
Upon completion of the public notice period, the company expects the EPA to complete the registration of nootkatone quickly thereafter.
About the collaboration with CDC
Evolva has partnered with the Center of Disease Control and Prevention (CDC) since 2014. In 2017, Evolva was awarded a CDC Biomedical Advanced Research and Development Authority (BARDA) contract with the key objective of advancing the development of nootkatone and nootkatone-based products for protection against mosquito-borne diseases including dengue and Zika. This work has been funded with federal funds from CDC and managed by the Office of the Assistant Secretary for Preparedness and Response (ASPR), BARDA, under Contract No. HHSO100201700015C.